BioCentury Inc.

We are excited to welcome Biosparc, Russell Reynolds Associates, and Stifel as sponsors of the 12th BioCentury & BayHelix China Healthcare Summit!   Biosparc is a life sciences industrial park in Suzhou, developed by Temasek and Suzhou Industrial Park, dedicated to advancing global innovation in biopharma, medtech, and AI-driven healthcare.   Russell Reynolds Associates is a global leadership advisory firm that helps organizations build transformational leaders and boards to meet today’s challenges and shape the future of business.   Stifel Institutional is a full-service investment bank providing strategic advisory and capital markets expertise to clients worldwide through its integrated global platform.   Please join us in Shanghai Oct. 22-24 to get a firsthand look at China’s biotech ecosystem – and build your network with the right biopharmas, investors and CDMOs.     Meet the sponsors: https://lnkd.in/eqWPMv3W   See who you will meet: https://lnkd.in/dJMh2Ka   **Exclusive Rate for China’s Healthcare Entrepreneurs** Founders and senior leaders of China-based healthcare startups are invited to apply for our special China Entrepreneur Rate. 📩 Email conferences@biocentury.com to learn more. Can’t join in person? 🎥 Register instead for a Digital Pass, which includes two bonus days of virtual partnering.

FDA picking winners and losers through commissioner's national priority voucher program. Without predictable criteria, voucher may not be an effective incentive.

We are pleased to welcome the following biotechs who have joined the Presenting Company Track at the 12th China Healthcare Summit.   Antengene   Farnia Biologics S.A.S.   Freya Biosciences   Hummingbird Bioscience   Insilico Medicine   Lumosa Therapeutics Co., Ltd.   MacroLink   Meet the 2025 Presenting Company Class: https://lnkd.in/eu99k3nw   Given demand, our team just added more partnering tables at the venue! Register now and book your meetings – before the best partnering slots fill up: https://lnkd.in/dJMh2Ka

One week to go! 12th China Healthcare Summit (Shanghai, Oct. 22-24). See China's Innovation Moment for Yourself. ✅ Register: https://lnkd.in/dzWute3 Why Attend? ❖ Pharma: Record pharma attendance, including many flying over from HQ. ❖ China Biotech: Sold-out presenting company track. ❖ Investors: Casdin Capital, LLC, CBC Group, EDBI Pte Ltd, Eight Roads, EQT Life Sciences, Gilde Healthcare, MPM BioImpact, Morningside, Novo Holdings, Qiming Venture Partners, Sofinnova Partners, RA Capital Management and many more. ❖ Partnering: Most confirmed meetings since 2019. ❖ Networking: A few spots left for CEO & Investor Nightcap (first-come, first-served) ❖ Asia, ex-China: More than 10 Korea biotechs registered, too! Registrations this week, include: ❖ Bayer ❖ Bristol Myers Squibb ❖ CStone Pharmaceuticals ❖ Goldman Sachs ❖ GSK ❖ Hengrui Pharma ❖ Hua Medicine ❖ Innovent Biologics ❖ I-Mab Biopharma ❖ Insilico Medicine ❖ Pfizer ❖ Stifel Financial Corp. Hope to see you in Shanghai! #biotech #pharma #venturecapital #drugdevelopment #businessdevelopment

Matching degrader chemistry to the problem: @KymeraTx CEO Nello Mainolfi joins the #BioCenturyShow's @SelinaMKoch to discuss glues vs. heterobifunctional degraders, and how to prove a new modality on a new target without incurring biology risk

We are excited to welcome Insilico Medicine, O’Melveny and Meyer LLP and Unicycive as sponsors of the 12th BioCentury & BayHelix China Healthcare Summit!   Insilico Medicine is a global clinical-stage biotechnology company leveraging generative AI to connect biology, chemistry, and medicine for advanced drug discovery.   O'Melveny & Myers LLP the longest-running U.S. law firm in Shanghai, has a proven track record advising on China-related transactions in healthcare, biotech, and life sciences.   Unicycive Therapeutics (Nasdaq: UNCY) is a biotechnology company developing novel treatments for serious unmet medical needs.   Please join us in Shanghai Oct. 22-24 to get a firsthand look at China’s biotech ecosystem – and build your network with the right biopharmas, investors and CDMOs.     Meet the sponsors: https://lnkd.in/eqWPMv3W   See who you will meet: https://lnkd.in/dJMh2Ka   **Exclusive Rate for China’s Healthcare Entrepreneurs** Founders and senior leaders of China-based healthcare startups are invited to apply for our special China Entrepreneur Rate. 📩 Email conferences@biocentury.com to learn more. Can’t join in person? 🎥 Register instead for a Digital Pass, which includes two bonus days of virtual partnering.

GSK CSO Tony Wood has a vision for the pipeline that leverages shared biology to build strategic adjacencies in new indications. 🖋️ Lauren Martz, Executive Director, Biopharma Intelligence

With clinical proof-of-concept in multiple indications, a spate of deals and a growing pipeline, BBB shuttles may soon come of age. BioCentury analyzes the technologies beyond BBB shuttle therapies and their near and longer applications. 🖋️ Selina Koch, PhD, Executive Editor

We've just wrapped our latest BioCentury Inc. This Week podcast -- hope you'll take time to listen on Apple pods or Spotify or wherever you get your pods. We talk: Public Markets: Stephen Hansen joins to discuss his 4Q Preview, quoting a little Yogi Berra by saying it's 'deja vu all over again': Biotech’s fourth quarter began with a familiar feeling, Stephen says, with key indicators pointing toward an improving public market but political and regulatory uncertainty clouding the outlook. Just like this time last year... Is now the time that biotech will finally break through -- drop a comment below on what you think. US-China: Washington Editor Steve Usdin says the Senate’s move to limit access to Chinese CDMOs like WuXi Biologics & WuXi AppTec via a modified version of last year’s Biosecure Act is likely to pass this year. He explains why this version is different. Drug Pricing: Steve also gives his take on the latest developments in the White House’s “most favored nation” drug pricing negotiations with 17 biopharma companies -- and why it's coming down to individual companies making deals rather than PhRMA Deal-o-Rama: Stephen analyzes a pair of billion-dollar-plus M&A deals and explains why they're a great fit: the $4.7 billion deal by Novo Nordisk to acquire liver disease company Akero Therapeutics & the $1.5 billion takeout of in vivo cell therapy company Orbital Therapeutics by Bristol Myers Squibb & as ever Simone Fishburn is on hand to help make sense of it all Give us a listen! https://lnkd.in/gra2FGjB

AstraZeneca MFN deal similar to Pfizer's, raises questions for the entire industry. 🖋️ Steve Usdin, Washington Editor